Nucala and Adempas drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nucala (mepolizumab) and Adempas (riociguat). Common drug interactions include nausea among females.

The phase IV clinical study analyzes what interactions people have when they take Nucala and Adempas. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Nucala?

Nucala has active ingredients of mepolizumab. eHealthMe is studying from 26,883 Nucala users. Check the latest studies of Nucala.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

18 people who take Nucala and Adempas together, and have interactions are studied.

What are the common drug interactions of Nucala and Adempas, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Diarrhoea
White blood cell count decreased
Abdominal distension
Abdominal pain upper
Asthma
Bladder pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiac flutter (abnormal heart rhythm)
Colitis (inflammation of colon)

male:

n/a

What are the common drug interactions of Nucala and Adempas, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Blood pressure decreased
Cardiac flutter (abnormal heart rhythm)
Dizziness
Dyspnoea exertional (breathlessness or shortness of breath)
Fall
Frequent bowel movements
Headache (pain in head)
Hereditary angioedema (recurrent episodes of severe swelling)
Injection site erythema (redness at injection site)
Injection site rash

50-59:

n/a

60+:

Abdominal distension
Abdominal pain upper
Rectal haemorrhage (bleeding from anus)
Renal pain (kidney pain)
Retching (strong involuntary effort to vomit)
Vomiting
Weight decreased
Bladder pain
Constipation
Diarrhoea

What are the existing conditions these people have? *

Hereditary Angioedema (recurrent episodes of severe swelling): 8 people, 44.44%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 27.78%
Asthma: 5 people, 27.78%
Urinary Tract Infection: 1 person, 5.56%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 5.56%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 5.56%
Mixed Connective Tissue Disease (an autoimmune disease, in which the body's defence system attacks itself): 1 person, 5.56%
Interstitial Lung Disease: 1 person, 5.56%
Immune System Disorder: 1 person, 5.56%
Diabetes Mellitus Inadequate Control: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Nucala and Adempas?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously